ATE465754T1 - Nicht-immunsuppresives hiv tat-protein - Google Patents

Nicht-immunsuppresives hiv tat-protein

Info

Publication number
ATE465754T1
ATE465754T1 AT00953950T AT00953950T ATE465754T1 AT E465754 T1 ATE465754 T1 AT E465754T1 AT 00953950 T AT00953950 T AT 00953950T AT 00953950 T AT00953950 T AT 00953950T AT E465754 T1 ATE465754 T1 AT E465754T1
Authority
AT
Austria
Prior art keywords
lentivirus
tat
disclosed
immunosuppresive
tat protein
Prior art date
Application number
AT00953950T
Other languages
English (en)
Inventor
David Cohen
Original Assignee
Inist Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inist Inc filed Critical Inist Inc
Application granted granted Critical
Publication of ATE465754T1 publication Critical patent/ATE465754T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00953950T 1999-08-12 2000-08-10 Nicht-immunsuppresives hiv tat-protein ATE465754T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14852699P 1999-08-12 1999-08-12
PCT/US2000/021920 WO2001012220A1 (en) 1999-08-12 2000-08-10 Non-immunosuppressant hiv tat

Publications (1)

Publication Number Publication Date
ATE465754T1 true ATE465754T1 (de) 2010-05-15

Family

ID=22526144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00953950T ATE465754T1 (de) 1999-08-12 2000-08-10 Nicht-immunsuppresives hiv tat-protein

Country Status (7)

Country Link
US (2) US6667151B1 (de)
EP (1) EP1246647B1 (de)
AT (1) ATE465754T1 (de)
AU (1) AU785258B2 (de)
CA (1) CA2398269C (de)
DE (1) DE60044303D1 (de)
WO (1) WO2001012220A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8323928B2 (en) 1999-08-12 2012-12-04 Pin Pharma, Inc. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US20050244434A1 (en) * 1999-08-12 2005-11-03 Cohen David I Tat-based tolerogen compositions and methods of making and using same
US20070248618A1 (en) * 2004-03-16 2007-10-25 Cohen David I Tat-Based vaccine Compositions and Methods of Making and Using Same
EP1279404A1 (de) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Verwendung von HIV-1 Fragmenten oder Derivaten zur Bestimmung oder Aktivierung von Antigen-präsentierenden Zellen, oder zur Abgabe von Cargo-Molekülen für Impfung oder für Behandlung von anderen Erkrankungen
US20050208482A1 (en) * 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
DK2411043T3 (da) 2009-03-23 2013-10-21 Pin Pharma Inc Behandling af cancer med immunostimulatorisk hiv tat derivat-polypeptider
WO2011078426A1 (ko) 2009-12-24 2011-06-30 연세대학교 산학협력단 비만 억제 및 치료용 펩타이드
ES2748423T3 (es) 2012-12-06 2020-03-16 Pin Pharma Inc Tratamiento de trastornos inflamatorios, autoinmunitarios y neurodegenerativos con polipéptidos derivados de Tat inmunosupresores
JP2016533352A (ja) 2013-10-04 2016-10-27 ピーアイエヌ ファーマ インコーポレイテッド 免疫刺激性ＨＩＶ Ｔａｔ誘導体ポリペプチドによる癌の治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05506031A (ja) 1990-03-30 1993-09-02 スミスクライン・ビーチャム・コーポレイション 免疫不全ウイルス感染に伴う疾病の抑制
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
JPH11501310A (ja) * 1995-03-08 1999-02-02 ネオバック レトロウイルスの調節タンパク質から誘導された無毒の免疫原、抗体、製造方法およびそれらを含んでなる医薬組成物
FR2731355B1 (fr) * 1995-03-08 1997-05-30 Neovacs Nouveaux immunogenes, nouveaux anticorps, procede de preparation et compositions pharmaceutiques les renfermant

Also Published As

Publication number Publication date
EP1246647B1 (de) 2010-04-28
CA2398269C (en) 2013-04-09
AU6631100A (en) 2001-03-13
US6667151B1 (en) 2003-12-23
CA2398269A1 (en) 2001-02-22
US20030215797A1 (en) 2003-11-20
DE60044303D1 (de) 2010-06-10
WO2001012220A1 (en) 2001-02-22
AU785258B2 (en) 2006-12-07
WO2001012220A9 (en) 2002-07-11
EP1246647A4 (de) 2005-09-21
EP1246647A1 (de) 2002-10-09

Similar Documents

Publication Publication Date Title
DE60037450D1 (de) Funf-helix protein
ATE309378T1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
ATE465754T1 (de) Nicht-immunsuppresives hiv tat-protein
ATE158415T1 (de) Kationisierte antikörper gegen intrazelluläre eiweisse
CY1107447T1 (el) Ετερολογη εκφραση πρωτεϊνων των neisseria
CY1110878T1 (el) Διαδικασιες για την μετρηση της ισχυος του glatiramer acetate
AR029759A1 (es) Variante de glucoamilasa original, una construccion de adn, un vector de expresion recombinante, una celula, un proceso para convertir almidon, uso de una variante de glucoamilasa para un proceso de fermentacion y metodo para mejorar la estabilidad termica.
DK1149905T3 (da) Fremgangsmåder og præparat til polypeptidteknologi
DE69620877D1 (de) Arzneimittelformulierungen für il-12
WO2001077951A8 (en) System and methods for group retirement plan administration
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
NO20030856D0 (no) Membranpenetrerende peptider og anvendelse av disse
BR0309963A (pt) Proteìna de fusão das proteìnas reguladoras/acessórias do hiv
DK208987A (da) Polypeptider og antistoffer, som er karakteristiske for papillomvirus, og deres anvendelse ved diagnostiske metoder og i vacciner
ATE431416T1 (de) Enzymatische synthese von deoxyribonucleotiden
NO20031860L (no) Kahalalid F
AU2001275438A1 (en) Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
KR100725637B1 (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
DK1144666T3 (da) Replikationsdeficient baculovirusekspressionssystem
TR200200802T2 (tr) Aşı
DK0491713T3 (da) Rubella El-peptider og C-peptider
FR2828934B1 (fr) Test de l'immunite cellulaire par des peptides fixes sur support solide
ES2157435T3 (es) Particulas retroviricas pseudotipadas.
ATE398188T1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties